AstraZeneca alleges patent infringement and seeks permanent injunction against same with regard to Seroquel, a drug for which the plaintiff owns a number of patents that begin to expire starting in September of next year and ending in 2017.
The Financial Express reported on 10/5/10 that generic interested in Seroquel, a drug that helps to control symptoms of schizophrenia but is also widely prescribed off-label and results in numerous side effects, including, but not limited to, tardive dyskinesia.
READ MORE SEROQUEL LEGAL NEWS
The lawsuit comes after AstraZeneca agreed to a $520 million settlement to settle allegations that the drug maker had participated in marketing initiatives for Seroquel that are deemed illegal, including paying kickbacks and marketing Seroquel for off-label uses not approved by the US Food and Drug Administration (FDA).
While doctors have the legal and medical authority to prescribe a drug off-label if they feel that the patient would benefit, manufacturers are not allowed to market or promote such off-label use.
Various states have been trumpeting their share(s) of the national settlement. Seroquel has been linked to diabetes, hyperglycemia and birth defects.